A PD-L2-based Immune Marker Signature Helps to Predict Survival in Resected Pancreatic Ductal Adenocarcinoma

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-019-0703-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

High Expression of CXCR4 May Predict Poor Survival in Resected Pancreatic Adenocarcinoma

British Journal of Cancer
Cancer ResearchOncology
2009English

Desmogleins as Prognostic Biomarkers in Resected Pancreatic Ductal Adenocarcinoma

British Journal of Cancer
Cancer ResearchOncology
2015English

EGFR, but Not COX‑2, Protein in Resected Pancreatic Ductal Adenocarcinoma Is Associated With Poor Survival

Oncology Letters
Cancer ResearchOncology
2019English

Prognostic Significance of XB130 Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma

World Journal of Surgical Oncology
SurgeryOncology
2014English

Infiltrating Immune Cells and Gene Mutations in Pancreatic Ductal Adenocarcinoma

British Journal of Surgery
Surgery
2016English

Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2014English

Nationwide Trends in Incidence, Treatment and Survival of Pancreatic Ductal Adenocarcinoma

European Journal of Cancer
Cancer ResearchOncology
2020English

A Panel of 12-lncRNA Signature Predicts Survival of Pancreatic Adenocarcinoma

Journal of Cancer
Oncology
2019English

The Impact of a History of Cancer on Pancreatic Ductal Adenocarcinoma Survival

United European Gastroenterology Journal
OncologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy